Article Text

PDF
SP0084 Understanding the Importance of Transparency When Using Opportunities to Work with the Pharmaceutical Industry
  1. A. Bosworth
  1. Chief Executive, National Rheumatoid Arthritis Society, Maidenhead, United Kingdom

Abstract

Ailsa Bosworth will reflect on the National Rheumatoid Arthritis Society's experience of working with the pharmaceutical industry over the preceding decade. The presentation will give examples of some collaborative projects the charity has worked on with the pharmaceutical industry, including directly funded and in-kind supported projects, and the accompanying value that has been accrued to the charity and to rheumatoid arthritis patients.

The presentation will then go on to consider factors that influence the charity's decisions to participate in individual project proposals and outline the codes of conduct which NRAS abides by when agreeing to work with industry. Finally, the presentation will consider national policy developments that affect UK health charities and explain how NRAS has begun to respond to these challenges through adopting new measures to further enhance transparency.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.6318

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.